BPC-157 is a laboratory-made chain of 15 amino acids, sold for tendon and joint injuries and healthy aging. It rests almost entirely on animal and cell research, plus a few clinic-run human reports without control groups. No benefit reaches even moderate confidence, and none has been tested for longevity. Reported risks are mostly theoretical or unmeasured, including uncertain product contents. Drug regulators treat it as unapproved. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT and AST | ≤ 25 U/L each | Liver safety |
| eGFR and creatinine | eGFR ≥ 90 mL/min/1.73 m² | Kidney clearance |
| CBC | Platelets 150–350 ×10⁹/L | Bleeding and clotting baseline |
| Fasting glucose and HbA1c | Glucose 75–90 mg/dL; HbA1c ≤ 5.4% | Metabolic safety marker |
| hs-CRP | < 1.0 mg/L | Inflammation baseline |
| TSH | 1.0–2.5 mIU/L | Thyroid safety marker |
| Blood pressure | < 120/80 mmHg | Theoretical blood-vessel widening |
| Cancer screening status | No numeric target; track completion of age-appropriate screening | Growth-signaling concern |
| Dilated eye exam (if retinal vascular disease) | No new abnormal vessel growth versus baseline | Vessel-growth concern |
Cadence: Baseline, about 4 weeks, end of course (about 8 weeks), then every 6–12 months while courses continue; earlier testing for symptoms